ライフサイエンスコーパス: hydroxyphenyl

1 Bisphenol A, bisphenol AF, and 2-2-bis(p-hydroxyphenyl)-1,1,1-trichloroethane (group 1) strongly

2 heylene-1,2-diamine (13) and (+/-)-2,3-di-(2-hydroxyphenyl)-1,2-dihydroquinoxaline (17), respectively

3 1-phenylbut-1-en-2-yl)phenol (7) > E 4-(1-(4-hydroxyphenyl)-1-phenylbut-1-en-2-yl)phenol (6) > Z(4-(1

4 is(4-hydroxyphenyl)but-1-ene (3) > Z 4-(1-(4-hydroxyphenyl)-1-phenylbut-1-en-2-yl)phenol (7) > E 4-(1

5 cells 2-(2-fluoro-4-hydroxyphenyl)-3,5-bis(4-hydroxyphenyl)-1-propyl-1H-pyrrole 8b (EC(50) = 0.12 nM)

6 lls was determined for 2,3,5-tris(2-fluoro-4-hydroxyphenyl)-1-propyl-1H-pyrrole 8m (EC(50) = 23 nM),

7 The probe, 3-(2-hydroxyphenyl)-1-pyrenyl-2-propenone (PA-1) was synthesi

8 2-Hydroxy-8-(4-hydroxyphenyl)-1H-phenalen-1-one (1), the first reported

9 In this work, 4,4-difluoro-8-(4-hydroxyphenyl)- 2,6-diethynly-1,3,5,7-tetramethyl-4-bora

10 Synthesis of few 4(5)-(2-hydroxyphenyl)-2,5(4)-substituted imidazoles, which are

11 We previously identified (E)-2,4-bis(p-hydroxyphenyl)-2-butenal (BHPB), a tyrosine-fructose Mai

12 e)), 5, and [Re(O)(NAr)(hoz)2+] (hoz = 2-(2'-hydroxyphenyl)-2-oxazoline) (Ar = 2,4,6,-(Me)C(6)H(2); 4

13 er of potency as followed: E2 > 1,1-bis(4,4'-hydroxyphenyl)-2-phenylbut-1-ene (15) > 1,1,2-tris(4-hyd

14 The resultant 4-butyl-4-hydroxy-1-(4-hydroxyphenyl)-2-phenylpyrazolidine-3,5-dione (4-OH-OPB)

15 order formation of (Z)-2-(chloromethyl)-3-(2-hydroxyphenyl)-2-propenoic acid.

16 10 compounds, (1R,5R,9S)-(-)-9-hydroxy-5-(3-hydroxyphenyl-2-phenylethyl-2-azabicyclo[3.3.1]nona ne (

17 the synthetic retinoid, 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437), ef

18 6-[3-(1-Adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid increased R

19 proapoptotic retinoids 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid or N-(4-hyd

20 inducer AHPN {retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid} acts by re

21 The retinoid 6-[3'-(1-adamantyl)-4'-hydroxyphenyl]-2-naphthalenecarboxylic acid (AHPN) and i

22 hich was derived from 6-[3'-(1-adamantyl)-4'-hydroxyphenyl]-2-naphthalenecarboxylic acid (AHPN), and

23 thetic retinoid-related 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalenecarboxylic acid (AHPN)/CD437

24 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalenecarboxylic acid (CD437/AHPN)

25 sis of structurally rigid N-substituted-6-(3-hydroxyphenyl)3-azabicyclo[3.1.0]hexane and 3-methyl-4-(

26 r: RTI-5989-212[(3R)-N-[(1S)-1-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidin yl]methyl}-(2-me

27 9-97 [(3S)-7-hydroxy-N-[(1S)-1-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl ]methyl}-(2-me

28 -194 [(3R)-7-hydroxy-N-[(1S)-1-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl ]methyl}-(2-me

29 and (3R)-7-hydroxy-N-((1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl ]methyl}-2-met

30 ies, (3R)-7-hydroxy-N-[(1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl ]methyl}-2-met

31 (3 R)-7-hydroxy- N-((1 S)-1-{[(3 R,4 R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-meth

32 -240 [(3R)-7-hydroxy-N-[(1S)-1-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl ]methyl}-(2-me

33 and (3R)-7-hydroxy-N-[(1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl ]methyl}-(2-me

34 )-7-Hydroxy- N-[(1 S,2 S)-1-{[(3 R,4 R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl]methyl}-2-meth

35 d (3R)-7-hydroxy-N-[(1S,2S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidine- 1-yl]methyl}-2-me

36 and two new compounds, namely (Z)-1,6-bis(2-hydroxyphenyl)-3,4-diphenylhex-3-ene-1,6-dione (D1) and

37 , while in U2-OS/ERalpha cells 2-(2-fluoro-4-hydroxyphenyl)-3,5-bis(4-hydroxyphenyl)-1-propyl-1H-pyrr

38 ation and utilization of novel modified N-(4-hydroxyphenyl)-3,5-dinitrobenzamide-FePt/CNTs carbon pas

39 ification of a substituted pyrazole, 4-(4-(4-hydroxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)pyrog

40 These studies led to N-[(1S)-1-{[(3S)-4-(3-hydroxyphenyl)-3-methylpiperazin-1-yl]methyl}-2-methylpr

41 ncy of lead PDI inhibitor BAP2 (( E)-3-(3-(4-hydroxyphenyl)-3-oxoprop-1-en-1-yl)benzonitrile), we des

42 Its analogue, (E)-4-[3'-(1-adamantyl)-4'-hydroxyphenyl]-3-(3'-acetamidopropyloxy)cinnami c acid (

43 nyl}-1H-tetrazole, 5-{4-[3'-(1-adamantyl)-4'-hydroxyphenyl]-3-chlorobenzylidene}thiazolidine-2,4-dio

44 oid-related molecule 4-[3-Cl-(1-adamantyl)-4-hydroxyphenyl]-3-chlorocinnamic acid (3-Cl-AHPC) activat

45 (E)-4-[3'-(1-Adamantyl)-4'-hydroxyphenyl]-3-chlorocinnamic acid (3-Cl-AHPC) induces

46 (E)-4-[3-(1-Adamantyl)-4'-hydroxyphenyl]-3-chlorocinnamic acid (3-Cl-AHPC) induces

47 h AHPN/CD437 analog (E)-4-[3-(1-adamantyl)-4-hydroxyphenyl]-3-chlorocinnamic acid (3-Cl-AHPC) induces

48 that the novel compound 4-[3-(1-adamantyl)-4-hydroxyphenyl]-3-chlorocinnamic acid (3-Cl-AHPC), induce

49 r receptor ligand (E)-4-[3'-(1-adamantyl)-4'-hydroxyphenyl]-3-chlorocinnamic acid (3-Cl-AHPC), which

50 c acid (CD437/AHPN) and 4-[3-(1-adamantyl)-4-hydroxyphenyl]-3-chlorocinnamic acid (3-Cl-AHPC/MM002) a

51 comparable to that of 4-[3'-(1-adamantyl)-4'-hydroxyphenyl]-3-chlorocinnamic acid.

52 4-[3'-(1-adamantyl)-4'-hydroxyphenyl]-3-chlorophenyltetrazole, (2E)-5-{2-[3'-(1

53 Bisphenol A, bisphenol S, and 4-hydroxyphenyl 4-isoprooxyphenylsulfone (BPSIP) in urine

54 the BPA alternatives bisphenol S (BPS) and 4-hydroxyphenyl 4-isoprooxyphenylsulfone (BPSIP).

55 into a C=S group provided 5,7-dihydroxy-3-(4-hydroxyphenyl)-4(3H)-quinazolinethione (1ba), which acts

56 5,7-Dihydroxy-3-(4-hydroxyphenyl)-4(3H)-quinazolinone (1aa) acts as an agon

57 The well known MIF inhibitor (S,R)-3-(4-hydroxyphenyl)-4,5-dihydro-5-isoxazole acetic acid methy

58 essed the therapeutic efficacy of (S,R)-3-(4-hydroxyphenyl)-4,5-dihydro-5-isoxazole acetic acid methy

59 es with hydroxyphenylpyruvate and (S,R)-3-(4-hydroxyphenyl)-4,5-dihydro-5-isoxazole acetic acid methy

60 ctivity; a lead molecule, "ISO-1 ((S,R)-3-(4-hydroxyphenyl)-4,5-dihydro-5-isoxazole acetic acid methy

61 Treatment with the MIF antagonist (S,R)-3-(4-hydroxyphenyl)-4,5-dihydro-5-isoxazole acetic acid methy

62 )3-azabicyclo[3.1.0]hexane and 3-methyl-4-(3-hydroxyphenyl)-4-azabicyclo[4.1.0]heptanes.

63 udy, we identified (-)-N-[(1R,4S,5S,7R)-5-(3-hydroxyphenyl)-4-methyl-2-(3-phenylpropyl)-2-aza bicyclo

64 acetamide analogue (+)-N-[(1S,4R,5R,7S)-5-(3-hydroxyphenyl)-4-methyl-2-(3-phenylpropyl)-2-aza bicyclo

65 recently reported the discovery of (+)-5-(3-hydroxyphenyl)-4-methyl-2-(3-phenylpropyl)-2-azabicyclo[

66 M, raloxifene, the benzopyran SERM, (S)-3-(4-hydroxyphenyl)-4-methyl-2-[4-[2-(1-piperidinyl)ethoxy]ph

67 f iron chelators, three (S)-4,5-dihydro-2-(2-hydroxyphenyl)-4-methyl-4-thiazolecarboxylic acid (DADFT

68 revented by the ERalpha antagonist 1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol

69 approved potentiator N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide

70 the identification of N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide

71 e lesser peak was identified as 4-(2-amino-3-hydroxyphenyl)-4-oxobutanoic acid glucoside (AHBG).

72 l meroterpenoids, namely, 2-(tetrahydro-5-(4-hydroxyphenyl)-4-pentylfuran-3-yl)-ethyl-4-hydroxybenzoa

73 and ER-beta-specific agonists [1,3,5-tris(4-hydroxyphenyl)-4-propyl-1H-pyrazole (PPT) and 2,3-bis(4-

74 the selective ERalpha agonist, 1,3,5-tris(4-hydroxyphenyl)-4-propyl-1H-pyrazole (PPT) as well as by

75 ERalpha selective agonist PPT (1,3,5-tris (4-hydroxyphenyl)-4-propyl-1H-pyrazole) and the ERbeta sele

76 acid (DADFT) and three (S)-4,5-dihydro-2-(2-hydroxyphenyl)-4-thiazolecarboxylic acid (DADMDFT) analo

77 ACHP (2-amino-6-[2-(cyclopropylmethoxy)-6-hydroxyphenyl]-4-(4-piperidinyl)-3-pyridinecarbonitrile)

78 Genistein (5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one) has been previousl

79 Compound 2 (3,6-dihydroxy-2-(3-hydroxyphenyl)-4H-chromen-4-one) was selected for pharma

80 inctive ligand in this series, 2-phenyl-3-(4-hydroxyphenyl)-5,7-bis(trifluoromethyl)-pyrazolo[1,5-a]p

81 ein kinase inhibitor 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)-1H-imidazole (SB 202190) an

82 inase inhibitor, and 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)1H-imidazole.

83 ation with SB202190 [4-(4-Fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)1H-imidazole], a p38 inhibit

84 inhibitor SB202190 [4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)1H-imidazole].

85 inhibitor SB202190 [4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)1H-imidazole].

86 inhibitor SB202190 [4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)1H-imidazole]; the effect of

87 estigate the mode of binding of 2-amino-4-(4-hydroxyphenyl)- 6-(1H-imidazol-2-ylmethylsulfanyl)pyridi

88 ed by formation of the water-insoluble 2-(2'-hydroxyphenyl)-6-[(125)I]iodo-4-(3H)-quinazolinone ((125

89 1-(3'-Formyl-4'-hydroxyphenyl)-8-(9'-anthryl)naphthalene (1) was prepare

90 N-[4a-(3-Hydroxyphenyl)-8a-methyl-2-(3-phenylpropyl)octahydroisoq

91 N-Substituted cis-4a-(3-hydroxyphenyl)-8a-methyloctahydroisoquinolines (6a-g) we

92 ne ((1R,5S)-(+)-14), and (1R,5S,9R)-(-)-5-(3-hydroxyphenyl)-9-methyl-2-phenethyl-2-azabicyclo[3.3.1]n

93 ona ne ((1R,5R,9S)-(-)-10), (1R,5S)-(+)-5-(3-hydroxyphenyl)-9-methylene-2-phenethyl-2-azabicyclo[3.3.

94 ds were notably high in their 2-hydroxy-N-(2-hydroxyphenyl) acetamide (HHPAA) concentration (40-48mic

95 enzoxazin-3-one (HBOA-d4) and 2-hydroxy-N-(2-hydroxyphenyl) acetamide (HHPAA-d4) were synthesized, to

96 by organohalide respiration using 3-chloro-4-hydroxyphenyl acetate (Cl-OHPA) as an electron acceptor.

97 rbamoylmethylene linked promoiety containing hydroxyphenyl acetic acid (HPA) derived ester and phosph

98 dministration of (R,S)-2-Amino-2-(2-chloro-5-hydroxyphenyl)acetic acid sodium salt (CHPG) an mGluR5 a

99 ors [10 microg of (RS)-2-amino-2-(2-chloro-5-hydroxyphenyl)acetic acid sodium salt] enhanced the disc

100 dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethyl)-3-(4-hydroxyphenyl)acrylamide (CHC-Mal), for selective detect

101 ring-opening of activated aziridines with 2-hydroxyphenyl acrylates and 2-aminophenyl acrylate, resp

102 sized from unlabeled (or [(2)H]-labeled) (4'-hydroxyphenyl)acrylic acids by reduction with D2 (or H2)

103 strate selectivity toward indole, phenyl, or hydroxyphenyl amino acids in plant AAADs.

104 xperiment indicate that the bond between the hydroxyphenyl and hydroxycyclohexyl rings is oriented pe

105 hat the binding tests homologize: both the 3-hydroxyphenyl and the 5-hydroxy-3-pyridyl ether of N-met

106 Diverse meso-aminophenyl-, hydroxyphenyl-, and phenyl-substituted heptamethine cyan

107 pair responses, the transport inhibitor N-(4-hydroxyphenyl)-arachidonamide (AM404) and the FAAH inhib

108 s and astrocytes, which is inhibited by N-(4-hydroxyphenyl)-arachidonamide (AM404).

109 scovered that the meta isomer of AM404, N-(3-hydroxyphenyl)arachidonoylamide (3-HPAA), is a substrate

110 N-(4-Hydroxyphenyl)arachidonoylamide (AM404) is an inhibitor

111 inhibited in a dose-dependent manner by N-(4-hydroxyphenyl)arachidonylamide (AM404).

112 previous work, several 1-alkyl-2,3,5-tris(4-hydroxyphenyl)aryl-1H-pyrroles with chlorine or fluorine

113 ive species present upon the photolysis of 3-hydroxyphenyl azide in aqueous solution.

114 The intermediate produced by photolysis of 3-hydroxyphenyl azide is much more reactive than the inter

115 produced upon photolysis of phenyl azide, 3-hydroxyphenyl azide, 3-methoxyphenyl azide, and 3-nitrop

116 ures--using a library of 56 N-(3,5-dibromo-4-hydroxyphenyl)benzamides.

117 nversion of dibenzothiophene sulfone to 2-(2-hydroxyphenyl)-benzenesulfinic acid, is catalyzed by a u

118 -phenylenediamine to give 2-(3,5-dimethoxy-4-hydroxyphenyl)benzimidazole coupled with the reduction o

119 yrene resin was reacted with 4-(5'-formyl-2'-hydroxyphenyl)benzoic acid and 4-(5'-formyl-2'-hydroxyph

120 2-(2'-Hydroxyphenyl)benzoxazole (HBO) derivatives represent an

121 related compounds [e.g., derivatives of 2-(2-hydroxyphenyl)benzoxazole and hydrogen-bonded complexes

122 , the rotational energy barrier of 2- (2',6'-hydroxyphenyl)benzoxazole is determined to be 10.5 kcal/

123 NR2B antagonist, Ro25-6981 [R-(R,S)-alpha-(4-hydroxyphenyl)-beta-methyl-4-(phenylmethyl)-1-piperidine

124 ctive antagonist Ro25-6981 [R-(R,S)-alpha-(4-hydroxyphenyl)-beta-methyl-4-(phenylmethyl)-1-piperidine

125 nimodipine, or Ro 25-6981 [R-(R,S)-alpha-(4-hydroxyphenyl)-beta-methyl-4-(phenylmethyl)-1-piperidine

126 receptors using RO25-6981 [R-(R,S)-alpha-(4-hydroxyphenyl)-beta-methyl-4-(phenylmethyl)-1-piperidine

127 2B receptor ifenprodil and R-(R, S)-alpha-(4-hydroxyphenyl)-beta-methyl-4-(phenylmethyl)-1-piperidine

128 yl)phenol (6) > Z(4-(1-(4-ethoxyphenyl)-1-(4-hydroxyphenyl)but-1-en-2-yl)phenol (12) > 4-OHTAM.

129 henyl)-2-phenylbut-1-ene (15) > 1,1,2-tris(4-hydroxyphenyl)but-1-ene (3) > Z 4-(1-(4-hydroxyphenyl)-1

130 phenylethylidene)bisphenol (BPAP), 2,2-bis(4-hydroxyphenyl)butane (BPB), 4,4'-dihydroxydiphenylmethan

131 3)O(2), using the photosensitizer meta-tetra(hydroxyphenyl)chlorin (mTHPC).

132 to solubilize the photosensitizer meta-tetra(hydroxyphenyl)chlorin.

133 9(11)-en-24-one; 4-(2Z)-2-decen-1-yl-5-[1-(4-hydroxyphenyl)decyl]-1,2-benzenediol; 8-[(2E)-3,7-dimeth

134 ic equilibrium behavior exhibited by a new o-hydroxyphenyl diazepine derivative when the compound is

135 iscyclohexano-fused Mn(III) complexes of bis(hydroxyphenyl)dipyrromethenes, 4a-c, as potent and orall

136 rystal X-ray analysis of 6a shows that the 3-hydroxyphenyl equatorial conformation is favored in the

137 The 3-hydroxyphenyl equatorial conformation is responsible for

138 mbled monolayers switches a nonelectroactive hydroxyphenyl ester to an electroactive hydroquinone, pr

139 nfirmed using a model compound, 1-(2-amino-3-hydroxyphenyl)ethan-1-one, which is an aminophenol lacki

140 ogue of this ligand (2) in 9 steps from 2-(4-hydroxyphenyl)ethanol and in 34% overall yield.

141 phenone); and triclosan (2,4,4'-trichloro-2'-hydroxyphenyl ether).

142 The resulting 3-pyridyl and m-hydroxyphenyl ethers have high alpha4beta2 affinity and

143 iomimetic synthesis of 3,4-DHPEA-EDA [2-(3,4-hydroxyphenyl) ethyl (3S,4E)-4-formyl-3-(2-oxoethyl)hex-

144 abeled using (111)In-DOTA or (125)I-iodo-((4-hydroxyphenyl)ethyl) maleimide (HPEM).

145 somer (S)-N(1)-methyl-2-[2'-(3''-methoxy-4''-hydroxyphenyl)ethyl]-1,2,3,4-tetrahydroqui noline is rep

146 ne to (S)-N(1)-methyl-2-[2'-(3''-methoxy-4''-hydroxyphenyl)ethyl]-1,2,3,4-tetrahydroqui noline.

147 peptide thioesters containing one or more p-(hydroxyphenyl)glycine (pHPG) residues and L-serine, some

148 During this process, N-(4-hydroxyphenyl)glycine served as a source of N doping and

149 that structural rigid compounds having the 3-hydroxyphenyl group locked in the piperidine equatorial

150 uent, in particular, the 1-pyrrolyl or the 4-hydroxyphenyl group.

151 nt of the 3-hydroxyl substituent of the 4-(3-hydroxyphenyl) group of JDTic with a H, F, or Cl substit

152 to produce the three primary lignin units: p-hydroxyphenyl, guaiacyl, and syringyl, respectively, whe

153 , resulting in a lignin polymer containing p-hydroxyphenyl (H), catechyl (C) and guaiacyl (G) units.

154 t secondary cell walls and is derived from p-hydroxyphenyl (H), guaiacyl (G), and syringyl (S) monoli

155 oic acid (Ahppa) and the novel 2-amino-6-(4'-hydroxyphenyl)hexanoic acid (Ahpha), respectively.

156 al modification performed on a 4-methyl-4-(4-hydroxyphenyl)hydantoin series is described which result

157 oxy-4'-methoxyphenyl)hydracrylic acid, 3-(3'-hydroxyphenyl)hydracrylic acid, 3'-methoxy-4'-hydroxyphe

158 The C24-N-(4-p-hydroxyphenyl)imidazol-5-yl constitution found in amaran

159 oles A, C, and D is replaced by a C24-O-(4-p-hydroxyphenyl)imidazole-2-carboxylate motif in amaranzol

160 (+)-4-[3,4-Dimethyl-2,5-dioxo-4-(4-hydroxyphenyl)imidazolidin-1-yl]-2-(trifluorom ethyl)ben

161 In this study, 3,3-bis(4-hydroxy-3-((E)-((4-hydroxyphenyl)imino)methyl) phenyl)isobenzofuran-1(3H)-o

162 as the free ligand 2-[[(3,5-di-tert-butyl-2-hydroxyphenyl)imino]methyl]-4,6-di-tert-butylphenol 1.

163 of 1-(4-(3,5-bis(benzo[d]thiazol-2-ylthio)-4-hydroxyphenyl) in the presence of p-toluenesulfinic acid

164 the level of incorporation of H-monomers (p-hydroxyphenyl) into cell walls.

165 G:S compositional bounds of normal plants; p-hydroxyphenyl levels are reported to reach a maximum of

166 el lignin consisting almost exclusively of p-hydroxyphenyl lignin subunits, and moreover exhibit subs

167 re directly derived from the precursors of p-hydroxyphenyl lignin, through the action of a dual speci

168 The half-component of TP2, i.e., 4,6-bis(4-hydroxyphenyl)-m-xylene (BX), deduced by simple structur

169 In this work, the CNT-mer entails a N-hydroxyphenyl maleimide functionality to be utilized in

170 AP metabolites, including S-(5-acetylamino-2-hydroxyphenyl)mercaptopyruvic acid (VI, formed by a Cys-

171 e NR4A1 antagonists 1,1-bis(3'-indolyl)-1-(p-hydroxyphenyl)methane (DIM-C-pPhOH) and a related p-carb

172 the TR3 antagonist 1,1-bis(3'-indolyl)-1-(p-hydroxyphenyl)methane (DIM-C-pPhOH) decreased proliferat

173 1,1-Bis(3'-indolyl)-1-(p-hydroxyphenyl)methane (DIM-C-pPhOH) is a recently discov

174 2-chloro-4-phenylphenol, and bis(5-chloro-2-hydroxyphenyl)methane) antimicrobial agents found in bio

175 triclocarban, 0.372 muM for bis-(5-chloro-2-hydroxyphenyl)methane, 4.89 muM for 2-chloro-4-phenyl ph

176 yl]carbonyl]pentyl]amino]-1-[(3,5-d ibromo-4-hydroxyphenyl)methyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3

177 yl]carbonyl]pentyl]amino]-1-[ (3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3

178 ormation of the small molecule 3-amino-5-[(p-hydroxyphenyl)methyl]-4,4-dimethyl-2-pyrrolidinone (AHDP

179 receptor inhibitor N2-(diphenylacetyl)-N-[(4-hydroxyphenyl)methyl]-D-arginine-amide (BIBP3226) enhanc

180 nist BIBP3226 [(R)-N2-(diphenylacetyl)-N-[(4-hydroxyphenyl)methyl]-D-arginine-amide], consistent with

181 1 inhibitor GW5074 (5-iodo-3-[(3,5-dibromo-4-hydroxyphenyl) methylene]-2-indolinone) or the absence o

182 , 1,3-propanediol, and a Schiff-base (2-[[(2-hydroxyphenyl) methylene]amino]-1,3-propanediol) forms a

183 triphenylmethane-derivative (aurin; 4-[bis(p-hydroxyphenyl)methylene]-2,5-cyclohexadien-1-one) was id

184 tion of the aurone hispidol (6-hydroxy-2-[(4-hydroxyphenyl)methylidene]-1-benzofuran-3-one) as a majo

185 , Tyr(101), and Lys(134) as contacting the 4-hydroxyphenyl moiety of the inhibitor.

186 o groups to N-phenylpropyl-4beta-methyl-5-(3-hydroxyphenyl)morphan (4) led to compounds that were pur

187 antagonist N-phenylpropyl-4beta-methyl-5-(3-hydroxyphenyl)morphan (4) led to kappa selective pure op

188 ppa opioid receptor antagonist from the 5-(3-hydroxyphenyl)morphan class of opioids.

189 Several 4-(4-hydroxyphenyl)-N-arylhydantoins displayed partial agonis

190 Both of the enantiomers of 5-(3-hydroxyphenyl)-N-phenylethylmorphan with C9alpha-methyl,

191 ydroxy-2-dipropylaminotetralin to S-(-)-3-(3-hydroxyphenyl)-N-propylpiperidine, which is an agonist f

192 s that resulted in the aromatic-substituted (hydroxyphenyl)naphthol sulfonamides.

193 or the species-specific optimization of the (hydroxyphenyl)naphthols, a combinatorial approach was ap

194 ut predictably increased the proportion of p-hydroxyphenyl (P) units relative to the normally dominan

195 nal groups such as p-hydroxymethyl phenyl, p-hydroxyphenyl, p-cyanophenyl, p-nitrophenyl, and p-formy

196 analogue, FEDPN (5-fluoro-(2R,3S)-2,3-bis(4-hydroxyphenyl)pentanenitrile), has an 8.3-fold absolute

197 binant rat and human FAAH, we show that 5-(4-hydroxyphenyl)pentanesulfonyl fluoride (AM3506) has simi

198 t and selective FAAH inhibitor, AM3506 (5-(4-hydroxyphenyl)pentanesulfonyl fluoride).

199 ) possess in addition the rare 2-amino-5-(4'-hydroxyphenyl)pentanoic acid (Ahppa) and the novel 2-ami

200 On the other hand, modifications of the 3-hydroxyphenyl pharmacophore, but not the 7-hydroxy Tic p

201 addition manner to give a high yield of a 4-hydroxyphenyl phenyl(2,4,6-trimethylphenyl)phosphinite w

202 droxyphenyl)benzoic acid and 4-(5'-formyl-2'-hydroxyphenyl)phenyl propionic acid, respectively, in th

203 We report the discovery of new 4-hydroxyphenyl phosphonium salt derivatives active in the

204 out by electrochemical oxidation of 1-(4-(4-hydroxyphenyl)piperazin-1-yl)ethanone in the presence of

205 zazoles leading to the disubstituted 1-(4-(4-hydroxyphenyl)piperazin-1-yl)ethanone.

206 of N-methyl and N-phenylpropyl 3-methyl-4-(3-hydroxyphenyl)piperazines (8a,b) gives (4a,b), which are

207 ly reported that N-substituted 3-methyl-4-(3-hydroxyphenyl)piperazines were a new class of opioid rec

208 of AT-076 (1), (R)-7-hydroxy-N-((S)-1-(4-(3-hydroxyphenyl)piperidin-1-yl)-3-methylbutan-2-yl)-1, 2,3

209 altrindole, and atrans-(3R,4R)-dimethyl-4-(3-hydroxyphenyl) piperidine (JDTic) are selective kappa op

210 of the N-substituted trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine (1) class of opioid receptor an

211 ned analogues of the trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine (4) class of opioid receptor pu

212 r the antagonist activity observed in the (3-hydroxyphenyl)piperidine antagonists.

213 antagonist from the trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine class of opioid antagonist.

214 antagonist from the trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine class of opioid antagonists.

215 r a mu ligand of the trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine class to interact with the mu o

216 n of the N-phenethyl trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine derivative 3, prototypical mu-o

217 rates that the N-substituted 3,4-dimethyl-(3-hydroxyphenyl)piperidine-derived antagonist, JDTic, reli

218 N-substituted trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidines (2a,b) are opioid receptor ant

219 ither axial or equatorial, similar to the (3-hydroxyphenyl)piperidines 4.

220 The series of trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidines have been widely investigated

221 nols with (2 E)-3-( N, N-dimethylamino)-1-(2-hydroxyphenyl)prop-2-en-1-ones and the subsequent cascad

222 ed by electropolymerization of N-(3-(4-(2-(4-hydroxyphenyl)propan-2-yl)phenoxy)propyl) 3-(5-hydroxy-1

223 eight bisphenol analogues, namely 2,2-bis(4-hydroxyphenyl)propane (BPA), 4,4'-(hexafluoroisopropylid

224 Bisphenol A (2,2-bis[4-hydroxyphenyl]propane, BPA), the monomer used to produce

225 y Cramer, e.g., ethyl 3-(3,5-di-tert-butyl-4-hydroxyphenyl) propanoate and benzenepropanoic acid, 3,5

226 Methyl and ethyl 3-(3,5-di-tert-butyl-4-hydroxyphenyl) propanoate were found to be degradation p

227 ogenic methine on the photoproduct, rac-2-(p-hydroxyphenyl)propanoic acid (rac-9), is formed by closu

228 Mutremdamide A displays a rare 2-amino-3-(2-hydroxyphenyl)propanoic acid and a new N(delta)-carbamoy

229 e metabolism of catechin derivative and 3-(4-hydroxyphenyl)propanoic acid continued slowly for at lea

230 actic, phenyllactic, 3-phenylpropanoic, 3-(4-hydroxyphenyl)propanoic and 5-oxopyrrolidine-2-carboxyli

231 zed a fluoroethyl analogue of DPN (2,3-bis(4-hydroxyphenyl)propanonitrile), a known ERbeta-selective

232 sted 5-exo-dig reductive cyclization of 1-(2-hydroxyphenyl)-propargyl alcohols is achieved for 2-alky

233 UV-protective compounds such as 3-(3-hydroxyphenyl)propionate, apigenin, and naringenin, were

234 retion of the microbial-host cometabolite (3-hydroxyphenyl)propionate-sulfate and disrupted metabolit

235 These catabolites were 3-(3'-methoxy-4'-hydroxyphenyl)propionic acid, 3-(3'-hydroxy-4'-methoxyph

236 radation of the environmental pollutant 3-(3-hydroxyphenyl)propionic acid.

237 eport the synthesis of methyl esters of 3-(4-hydroxyphenyl)propionic, 3-(3,4-dihydroxyphenyl)propioni

238 A high concentration of 2-(4-hydroxyphenyl)-propionic acid was observed, suggesting t

239 yl)-4-propyl-1H-pyrazole (PPT) and 2,3-bis(4-hydroxyphenyl) propionitrile (DPN), respectively].

240 the ERbeta selective agonist DPN (2,3-bis (4-hydroxyphenyl) propionitrile) alone and in combination i

241 The ERbeta agonists 2,3-bis(4-hydroxyphenyl)-propionitrile and ERB041 also down-regula

242 ta, propylpyrazole triol (PPT) and 2,3-bis(4-hydroxyphenyl) proprionitrile (DPN), respectively, were

243 with the ER-beta selective agonist 2,2-bis(4-hydroxyphenyl)-proprionitrile (DPN), 17beta-estradiol (E

244 cha young wines were prone to contain higher hydroxyphenyl-pyranoanthocyanin concentrations.

245 sins (highest values for Syrah wines) and 10-hydroxyphenyl-pyranoanthocyanins (highest values for Mer

246 ected by disappearance during aging, whereas hydroxyphenyl-pyranoanthocyanins increased their contrib

247 e (via dehydrogenative homocoupling) or N-(o-hydroxyphenyl)pyrazole (via C-H oxygenation) or their mi

248 y dilute conditions (ca. 10 times) then N-(o-hydroxyphenyl)pyrazoles were the major or the sole produ

249 ion: see text] A variety of substituted 3-(2-hydroxyphenyl)pyridines have been prepared regioselectiv

250 nhibited the ability of MIF to tautomerize 4-hydroxyphenyl pyruvate.

251 genase (HPPD) catalyzes the conversion of (4-hydroxyphenyl)pyruvate (HPP) to homogentisate (HG).

252 Di- and triketone inhibitors of (4-hydroxyphenyl)pyruvate dioxygenase (HPPD) are both effec

253 (4-Hydroxy)mandelate synthase (HmaS) and (4-hydroxyphenyl)pyruvate dioxygenase (HPPD) are two alpha-

254 (4-Hydroxyphenyl)pyruvate dioxygenase (HPPD) catalyzes the

255 (4-Hydroxyphenyl)pyruvate dioxygenase (HPPD) incorporates b

256 iron enzymes that use the same substrate, (4-hydroxyphenyl)pyruvate, but exhibit two different genera

257 tion of L-homotyrosine from acetyl-CoA and 4-hydroxyphenyl-pyruvate is found from the sequenced genom

258 ctivity using l-dopachrome methyl ester or 4-hydroxyphenyl pyruvic acid as substrates.

259 Mean N-4-hydroxyphenyl retinamide plasma level (day 7, steady-sta

260 We explored efficacy of N-(4-hydroxyphenyl) retinamide (4-HPR) and (-)-epigallocatech

261 udy examines the synergistic actions of N-(4-hydroxyphenyl) retinamide (4-HPR) and paclitaxel (PTX) t

262 We identify N-(4-hydroxyphenyl) retinamide (4-HPR) as effective in protec

263 N-(4-Hydroxyphenyl) retinamide (4-HPR) is a synthetic retinoi

264 ual disease with the cytotoxic retinoid N-(4-hydroxyphenyl) retinamide (4-HPR; fenretinide) may decre

265 N-(4-hydroxyphenyl) retinamide [4-HPR], a synthetic retinoid,

266 quiescence to cellular activation with N-(4-hydroxyphenyl) retinamide activates coordinated stress p

267 e retinoic acid derivative fenretinide (N-(4-hydroxyphenyl) retinamide; HPR) exerts therapeutic effec

268 e sensitivity of breast cancer cells to N-(4-hydroxyphenyl)retinamide (4-HPR) by suppressing nitric o

269 The synthetic retinoid fenretinide N-(4-hydroxyphenyl)retinamide (4-HPR) has shown promise for t

270 cytotoxicity of the synthetic retinoid N-(4-hydroxyphenyl)retinamide (4-HPR) in tumor cells.

271 The synthetic retinoid N-(4-hydroxyphenyl)retinamide (4-HPR) induces apoptosis in a

272 N-(4-Hydroxyphenyl)retinamide (4-HPR), a dihydroceramide synt

273 n with low micromolar concentrations of N-(4-hydroxyphenyl)retinamide (4-HPR), which downmodulates cy

274 ation of pharmacological agents such as N-(4-hydroxyphenyl)retinamide (4-HPR, fenretinide), by treatm

275 g the major metabolites of 4-HPR, 4-oxo-N-(4-hydroxyphenyl)retinamide (4-oxo-4-HPR) showed the highes

276 The synthetic retinoid N-(4-hydroxyphenyl)retinamide (4HPR) has shown potential as a

277 N-(4-hydroxyphenyl)retinamide (4HPR), a synthetic retinoid ef

278 N-(4-hydroxyphenyl)retinamide (HPR) potently and reversibly r

279 N-(4-Hydroxyphenyl)retinamide up-regulated ELF3, c-Jun, Rb2/p

280 henyl]-2-naphthalene carboxylic acid or N-(4-hydroxyphenyl)retinamide.

281 Order parameters of the hydroxyphenyl ring determined by the 1H-13C DIPSHIFT exp

282 as 1H NMR cross-relaxation rates, locate the hydroxyphenyl ring of the ligand near the lipid glycerol

283 essentially hydrophobic environment of its p-hydroxyphenyl site and the absence of direct hydrogen bo

284 ates three key features: (a) a bis(4-amino-3-hydroxyphenyl)squaraine core with bright deep-red fluore

285 6a-g can exist in conformations where the 3-hydroxyphenyl substituent is either axial or equatorial,

286 Products containing a 2-(2'-hydroxyphenyl) substituent undergo excited state intramo

287 avylium salts substituted at 4-position with hydroxyphenyl substituents were synthesized by acidic co

288 tions with GLY300, observed for the potent 4-hydroxyphenyl substituted inhibitors.

289 n achieved through alkylation/acylation of 2-hydroxyphenyl-substituted para-quinone methides followed

290 ted binding orientation of the 3,5-dibromo-4-hydroxyphenyl substructure and revealed a strong prefere

291 f the 5-HT(7) receptor antagonist (2R)-1-[(3-hydroxyphenyl)sulfonyl]-2 -(2-(4-methyl-1-piperidinyl)et

292 ushroom tyrosinase inhibitors of a series of hydroxyphenyl thiosemicarbazones (1-5): one of them reve

293 small wheels of Fuji apples treated with the hydroxyphenyl thiosemicarbazones.

294 ing lignin to a 10-fold higher fraction of p-hydroxyphenyl units at the expense of syringyl units.

295 in content, and preferential accumulation of hydroxyphenyl units in lignin, indicating that the CSE e

296 ced lignin deposition, increased levels of p-hydroxyphenyl units in the lignin polymer, and a relativ

297 Benzoic acid (38.4mug/ml), 4-hydroxy-5-(3'-hydroxyphenyl)-valeric acid (26.2mug/ml) and phenylaceti

298 hydrolyzed by the esterase CA activity to 2-hydroxyphenyl-vinylsulfonic acids, which thereafter bind

299 1-(4-(3,5-Bis(benzo[d]thiazol-2-ylthio)-4-hydroxyphenyl) was converted into 2-(benzo[d]thiazol-2-y

300 The contributions of p-hydroxyphenyls were generally similar to the guaiacyl so